SFCA3006: Significantly Greater Improvement in Pre-Dose FEV1 Seen with FSC500/50 vs. SAL50

Endpoint

(15%)

(2%)

(11%)

(10%)

*P=0.012 vs SAL

*

? FEV1 (ml)

Previous slide

Next slide

Back to first slide

View graphic version